|
gptkbp:instanceOf
|
gptkb:beta_blocker
gptkb:drug
|
|
gptkbp:approvedBy
|
1962
|
|
gptkbp:ATCCode
|
C08DA01
|
|
gptkbp:bioavailability
|
20–35% (oral)
|
|
gptkbp:brand
|
gptkb:Calan
gptkb:Isoptin
gptkb:Verelan
Covera-HS
|
|
gptkbp:CASNumber
|
52-53-9
|
|
gptkbp:chemicalFormula
|
C27H38N2O4
|
|
gptkbp:contraindication
|
gptkb:second-_or_third-degree_AV_block
hypotension
cardiogenic shock
severe left ventricular dysfunction
|
|
gptkbp:discoveredBy
|
gptkb:Knoll_AG
|
|
gptkbp:drugInteraction
|
gptkb:digoxin
beta blockers
statins
|
|
gptkbp:eliminationHalfLife
|
2.8–7.4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasGenericVersion
|
true
|
|
gptkbp:KEGGID
|
D08602
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits L-type calcium channels
|
|
gptkbp:MedlinePlusID
|
a684027
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
454.6 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
2520
CHEMBL1760
DB00661
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
hypotension
bradycardia
|
|
gptkbp:UNII
|
CJ0O37KU29
|
|
gptkbp:usedFor
|
gptkb:arrhythmia
gptkb:angina
hypertension
cluster headache
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Cluster_headache
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Verapamil
|